Petmed Express Inc

Análisis de la acción Petmed Express Inc (PETS)

$1.220

+0.041 (+3.39%)Al cierre

Loading chart…
Máximo
1.265
Apertura
1.170
Precio medio ponderado por volumen
1.22
Volumen
272.24K
Capitalización
86.14M
Mínimo
1.170
Importe
331.68K
EV/EBITDA, TTM
-0.93

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

Análisis de IA of Petmed Express Inc (PETS)

Mantener

PetMed Express Inc is not a good buy right now. The current price is $1.22, and the stock has a negative year-to-date change of -63.03%. Additionally, the RSI is at 47.78, indicating that the stock is neither overbought nor oversold, which suggests a lack of strong momentum. The recent acquisition proposal at $3.00 per share indicates potential value, but the company's deteriorating financials, including a net income loss of $6.14 million in the last quarter, pose significant risks.

Recomendaciones de analistas (5)

Comprar
2 Comprar
2 Mantener
1 Vender
Actual: 1.22
Mínimo
—
Promedio
—
Máximo
—

Morgan Stanley

2026-09-25

Precio objetivo

—

Infraponderar

Morgan Stanley

2025-04-17

Precio objetivo

$3.2

Vender

Lake Street

2024-08-07

Precio objetivo

$3.5

Mantener

Morgan Stanley

2024-06-12

Precio objetivo

$3.5

Vender

Lake Street

2024-06-12

Precio objetivo

$7

Compra fuerte

Métricas de valoración

El PER previsto actual de Petmed Express Inc (PETS) es 16.69, frente a su media de 5 años de -10.13.

PER previsto

Valor razonable
Media 5A P/E
-10.13
P/E actual
16.69
Sobrevalorada
97.15
Infravalorada
-117.42

EV/EBITDA previsto

Infravalorado
Media 5A EV/EBITDA
7.78
EV/EBITDA actual
-0.93
Sobrevalorada
14.50
Infravalorada
1.07

Precio/ventas previsto

Valor razonable
Media 5A P/S
0.76
P/S actual
0.17
Sobrevalorada
1.35
Infravalorada
0.16

Escenarios de precio de Alphio AI para PETS

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%PETS

$4.12

Precio del escenario

B

Base

Base · 50%PETS

$3.76

Precio del escenario

B

Bajista

Bajista · 25%PETS

$3.08

Precio del escenario

Ballenas con PETS en cartera

O

Oaktop Capital Management II, L.P.

+ Con en carteraPETS

-13.50%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-21 (ET)

09:00:00

PetMed Express Appoints Tamar Elkeles as Independent Director

2026-09-17 (ET)

09:00:00

PetMed Express Appoints Jeff Willard as CEO

2026-09-14 (ET)

16:30:00

PetMed Express Appoints Andrew Parry as CTO

2026-07-23 (ET)

08:30:00

PetMed Express Enters $37M Sale-Leaseback Agreement with Investor

2026-06-30 (ET)

10:00:00

PetMed Express Receives $3.00 Acquisition Proposal from SilverCape

Noticias

Preguntas frecuentes sobre PETS, respondidas por Alphio AI

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. It operates in the Consumer Non-Cyclicals sector (RETAIL-DRUG STORES AND PROPRIETARY STORES industry).

PetMed Express Inc is not a good buy right now. The current price is $1.22, and the stock has a negative year-to-date change of -63.03%. Additionally, the RSI is at 47.78, indicating that the stock is neither overbought nor oversold, which suggests a lack of strong momentum. The recent acquisition proposal at $3.00 per share indicates potential value, but the company's deteriorating financials, including a net income loss of $6.14 million in the last quarter, pose significant risks.

5 analysts cover PETS: 2 rate it Buy, 2 Hold and 1 Sell.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar